| Joanne Sherman Goldstein, MS, RN, APN, C | |
|
1814 E 2nd St, Scotch Plains, NJ 07076-1751 | |
| (908) 490-9090 | |
| Not Available |
| Full Name | Joanne Sherman Goldstein |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Psychiatric/mental Health |
| Location | 1814 E 2nd St, Scotch Plains, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700805264 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SP0808X | Clinical Nurse Specialist - Psychiatric/mental Health | 26NR05200800 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Joanne Sherman Goldstein, MS, RN, APN, C 1814 E 2nd St, Scotch Plains, NJ 07076-1751 Ph: (908) 490-9090 | Joanne Sherman Goldstein, MS, RN, APN, C 1814 E 2nd St, Scotch Plains, NJ 07076-1751 Ph: (908) 490-9090 |
News Archive
An increase in the number of injection drug users (IDUs) in eastern and southern Africa stands to harm efforts to control the spread of HIV/AIDS in the region, warned experts gathered at the World Forum Against Drug conference in Sweden on Monday, Agence France-Presse reports.
Zinc acetate lozenges may reduce the duration of the common cold by nearly 3 days, according to a recent analysis.
Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million.
In chronic kidney disease patients, different levels of anemia treatment have a beneficial effect on the heart and improve quality of life, according to a pair of studies appearing in the April 2009 issue of the Clinical Journal of the American Society Nephrology (CJASN).
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.
› Verified 4 days ago